Mercy Prabhudas
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mercy Prabhudas.
Nature Immunology | 2011
Mercy Prabhudas; Becky Adkins; Hayley A. Gans; Christopher L. King; Ofer Levy; Octavio Ramilo; Claire-Anne Siegrist
Infections in infants continue to be an important cause of morbidity and mortality worldwide. Understanding the immune mechanisms that operate in infants is necessary for the development of new approaches to improve the health of infants around the world.
Nature Immunology | 2015
Mercy Prabhudas; Elizabeth A. Bonney; Kathleen M. Caron; Sudhansu K. Dey; Adrian Erlebacher; Asgerally T. Fazleabas; Susan J. Fisher; Thaddeus G. Golos; Martin M. Matzuk; Joseph M. McCune; Gil Mor; Laura C. Schulz; Michael J. Soares; Thomas E. Spencer; Jack L. Strominger; Sing Sing Way; Koji Yoshinaga
Leaders gathered at the US National Institutes of Health in November 2014 to discuss recent advances and emerging research areas in aspects of maternal-fetal immunity that may affect fetal development and pregnancy success.
Journal of Immunology | 2014
Mercy Prabhudas; Dawn M. E. Bowdish; Kurt Drickamer; Maria Febbraio; Joachim Herz; Lester Kobzik; Monty Krieger; John D. Loike; Terry K. Means; Søren K. Moestrup; Steven R. Post; Tatsuya Sawamura; Samuel C. Silverstein; Xiang-Yang Wang; Joseph El Khoury
Scavenger receptors constitute a large family of proteins that are structurally diverse and participate in a wide range of biological functions. These receptors are expressed predominantly by myeloid cells and recognize a variety of ligands, including endogenous and modified host-derived molecules and microbial pathogens. There are currently eight classes of scavenger receptors, many of which have multiple names, leading to inconsistencies and confusion in the literature. To address this problem, a workshop was organized by the U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health to help develop a clear definition of scavenger receptors and a standardized nomenclature based on that definition. Fifteen experts in the scavenger receptor field attended the workshop and, after extensive discussion, reached a consensus regarding the definition of scavenger receptors and a proposed scavenger receptor nomenclature. Scavenger receptors were defined as cell surface receptors that typically bind multiple ligands and promote the removal of non-self or altered-self targets. They often function by mechanisms that include endocytosis, phagocytosis, adhesion, and signaling that ultimately lead to the elimination of degraded or harmful substances. Based on this definition, nomenclature and classification of these receptors into 10 classes were proposed. The discussion and nomenclature recommendations described in this report only refer to mammalian scavenger receptors. The purpose of this article is to describe the proposed mammalian nomenclature and classification developed at the workshop and to solicit additional feedback from the broader research community.
Journal of Immunology | 2017
Mercy Prabhudas; Cynthia L. Baldwin; Paul L. Bollyky; Dawn M. E. Bowdish; Kurt Drickamer; Maria Febbraio; Joachim Herz; Lester Kobzik; Monty Krieger; John D. Loike; Benita L. McVicker; Terry K. Means; Søren K. Moestrup; Steven R. Post; Tatsuya Sawamura; Samuel C. Silverstein; Robert C. Speth; Janice C. Telfer; Geoffrey M. Thiele; Xiang-Yang Wang; Samuel D. Wright; Joseph El Khoury
Scavenger receptors constitute a large family of proteins that are structurally diverse and participate in a wide range of biological functions. These receptors are expressed predominantly by myeloid cells and recognize a diverse variety of ligands including endogenous and modified host-derived molecules and microbial pathogens. There are currently eight classes of scavenger receptors, many of which have multiple names, leading to inconsistencies and confusion in the literature. To address this problem, a workshop was organized by the United States National Institute of Allergy and Infectious Diseases, National Institutes of Health, to help develop a clear definition of scavenger receptors and a standardized nomenclature based on that definition. Fifteen experts in the scavenger receptor field attended the workshop and, after extensive discussion, reached a consensus regarding the definition of scavenger receptors and a proposed scavenger receptor nomenclature. Scavenger receptors were defined as cell surface receptors that typically bind multiple ligands and promote the removal of nonself or altered-self targets. They often function by mechanisms that include endocytosis, phagocytosis, adhesion, and signaling that ultimately lead to the elimination of degraded or harmful substances. Based on this definition, nomenclature and classification of these receptors into 10 classes were proposed. This classification was discussed at three national meetings and input from participants at these meetings was requested. The following manuscript is a consensus statement that combines the recommendations of the initial workshop and incorporates the input received from the participants at the three national meetings.
Journal of the American Geriatrics Society | 2010
Kevin P. High; Richard T. D'Aquila; Rebecca Fuldner; Dale N. Gerding; Jeffrey B. Halter; Laura Haynes; William R. Hazzard; Lisa A. Jackson; Edward N. Janoff; Myron J. Levin; Susan G. Nayfield; Kristin L. Nichol; Mercy Prabhudas; Helen K. Talbot; Charles P. Clayton; Randi Henderson; Catherine M. Scott; Erika D. Tarver; Nancy Woolard; Kenneth E. Schmader
Goals for immunization in older adults may differ from those in young adults and children, in whom complete prevention of disease is the objective. Often, reduced hospitalization and death but also averting exacerbation of underlying chronic illness, functional decline, and frailty are important goals in the older age group. Because of the effect of age on dendritic cell function, T cell‐mediated immune suppression, reduced proliferative capacity of T cells, and other immune responses, the efficacy of vaccines often wanes with advanced age. This article summarizes the discussion and proceedings of a workshop organized by the Association of Specialty Professors, the Infectious Diseases Society of America, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Allergy and Infectious Diseases. Leading researchers and clinicians in the fields of immunology, epidemiology, infectious diseases, geriatrics, and gerontology reviewed the current status of vaccines in older adults, identified knowledge gaps, and suggest priority areas for future research. The goal of the workshop was to identify what is known about immunizations (efficacy, effect, and current schedule) in older adults and to recommend priorities for future research. Investigation in the areas identified has the potential to enhance understanding of the immune process in aging individuals, inform vaccine development, and lead to more‐effective strategies to reduce the risk of vaccine‐preventable illness in older adults.
American Journal of Reproductive Immunology | 2014
Koji Yoshinaga; Mercy Prabhudas; Christopher J. Davies; Kenneth L. White; Kathleen M. Caron; Thaddeus G. Golos; Asgerally T. Fazleabas; Bibhash C. Paria; Gil Mor; Soumen Paul; Xiaoqin Ye; Sudhansu K. Dey; Thomas E. Spencer; Robert Michael Roberts
This study describes the currently active research team created by participation of investigators who are eager to work together with other investigators of different disciplines on implantation research. The name of this group is ‘Interdisciplinary Collaborative Team for Blastocyst Implantation Research’. From now on we will call the group the Team. It started with the publication of an NIH Program Announcement.
Journal of the American Geriatrics Society | 2010
Kevin P. High; Richard T. D'Aquila; Rebecca Fuldner; Dale N. Gerding; Jeffrey B. Halter; Laura Haynes; William R. Hazzard; Lisa A. Jackson; Edward N. Janoff; Myron J. Levin; Susan G. Nayfield; Kristin L. Nichol; Mercy Prabhudas; Helen K. Talbot; Charles P. Clayton; Randi Henderson; Catherine M. Scott; Erika D. Tarver; Nancy Woolard; Kenneth E. Schmader
Goals for immunization in older adults may differ from those in young adults and children, in whom complete prevention of disease is the objective. Often, reduced hospitalization and death but also averting exacerbation of underlying chronic illness, functional decline, and frailty are important goals in the older age group. Because of the effect of age on dendritic cell function, T cell‐mediated immune suppression, reduced proliferative capacity of T cells, and other immune responses, the efficacy of vaccines often wanes with advanced age. This article summarizes the discussion and proceedings of a workshop organized by the Association of Specialty Professors, the Infectious Diseases Society of America, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Allergy and Infectious Diseases. Leading researchers and clinicians in the fields of immunology, epidemiology, infectious diseases, geriatrics, and gerontology reviewed the current status of vaccines in older adults, identified knowledge gaps, and suggest priority areas for future research. The goal of the workshop was to identify what is known about immunizations (efficacy, effect, and current schedule) in older adults and to recommend priorities for future research. Investigation in the areas identified has the potential to enhance understanding of the immune process in aging individuals, inform vaccine development, and lead to more‐effective strategies to reduce the risk of vaccine‐preventable illness in older adults.
Nature Immunology | 2017
Christina H Liu; Natalie D Abrams; Danielle M. Carrick; Preethi Chander; Johanna Dwyer; Michelle R J Hamlet; Francesca Macchiarini; Mercy Prabhudas; Grace L. Shen; Pushpa Tandon; Merriline M Vedamony
The US National Institutes of Health convened a workshop on disease-promoting chronic inflammation to identify the challenges and needs in the development of clinically feasible strategies for monitoring a persons inflammation status before, during and after disease occurrence.
Journal of the American Geriatrics Society | 2010
Kevin P. High; Richard T. D'Aquila; Rebecca Fuldner; Dale N. Gerding; Jeffrey B. Halter; Laura Haynes; William R. Hazzard; Lisa A. Jackson; Edward N. Janoff; Myron J. Levin; Susan G. Nayfield; Kristin L. Nichol; Mercy Prabhudas; Helen K. Talbot; Charles P. Clayton; Randi Henderson; Catherine M. Scott; Erika D. Tarver; Nancy Woolard; Kenneth E. Schmader
Goals for immunization in older adults may differ from those in young adults and children, in whom complete prevention of disease is the objective. Often, reduced hospitalization and death but also averting exacerbation of underlying chronic illness, functional decline, and frailty are important goals in the older age group. Because of the effect of age on dendritic cell function, T cell‐mediated immune suppression, reduced proliferative capacity of T cells, and other immune responses, the efficacy of vaccines often wanes with advanced age. This article summarizes the discussion and proceedings of a workshop organized by the Association of Specialty Professors, the Infectious Diseases Society of America, the American Geriatrics Society, the National Institute on Aging, and the National Institute of Allergy and Infectious Diseases. Leading researchers and clinicians in the fields of immunology, epidemiology, infectious diseases, geriatrics, and gerontology reviewed the current status of vaccines in older adults, identified knowledge gaps, and suggest priority areas for future research. The goal of the workshop was to identify what is known about immunizations (efficacy, effect, and current schedule) in older adults and to recommend priorities for future research. Investigation in the areas identified has the potential to enhance understanding of the immune process in aging individuals, inform vaccine development, and lead to more‐effective strategies to reduce the risk of vaccine‐preventable illness in older adults.
PMC | 2017
Mercy Prabhudas; Cynthia L. Baldwin; Paul L. Bollyky; Dawn M. E. Bowdish; Kurt Drickamer; Maria Febbraio; Joachim Herz; Lester Kobzik; John D. Loike; Benita L. McVicker; Terry K. Means; Søren K. Moestrup; Steven R. Post; Tatsuya Sawamura; Samuel C. Silverstein; Robert C. Speth; Janice C. Telfer; Geoffrey M. Thiele; Xiang-Yang Wang; Samuel D. Wright; Joseph El Khoury; Monty Krieger